Longer Sleep Duration Linked to Poorer Cognitive Outcomes in Older Adults
Overall, US older adults who reported longer sleep duration have poorer objective and subjective cognitive performance.
Sleep/Wake
Pear Therapeutics Seeks Approval for Rx Digital Therapeutic to Treat Insomnia, Depression
Pear Therapeutics is seeking marketing authorization from the Food and Drug Administration (FDA) for Somryst, a prescription digital therapeutic (PDT) intended for use in the treatment of adults with chronic insomnia and depression.
FDA: Boxed Warning, Contraindication Added to Several Insomnia Medications
A new Boxed Warning will be required in the prescribing information for several insomnia medications following reports of serious injuries and deaths associated with complex sleep behaviors where patients engaged in activities while not fully awake.
Cognitive Behavioral Therapy Effective for Prenatal Insomnia
Cognitive behavioral therapy is an effective nonpharmacologic treatment for insomnia during pregnancy.
Conversion From Sleep Disorder to Neurodegeneration Studied
Predictors of neurodegeneration from idiopathic REM sleep behavior disorder (iRBD) have been identified.
Melatonin: Range of Effects and Therapeutic Applications
Along with its effects on the endocrine system, melatonin is involved in regulating certain parameters of the cardiovascular system and central nervous system.
Insomnia in Late Pregnancy Associated With Perinatal Anxiety
Gestational insomnia is associated with anxiety symptoms, both during pregnancy and after childbirth.
Can Acupuncture Improve Sleep for Veterans With Traumatic Brain Injury and PTSD?
Acupuncture resulted in a significant improvement in sleep measures for veterans with mild traumatic brain injuries, disturbed sleep, and posttraumatic stress disorder.
Insomnia Increases Emotional Dysregulation, Impulsivity, and Suicidality in Bipolar Disorder
Sleep has important functions for the regulation of mood and emotion, and treatment of sleep disturbances in bipolar disorder may improve patient outcomes.
NDA Submitted for Novel Insomnia Treatment Lemborexant
The NDA includes data from two Phase 3 clinical trials (SUNRISE 1 and SUNRISE 2) which included approximately 2000 patients.
Next post in Sleep-Wake Disorders
